Accès ouvert
2025
article
OpenAlex
Sibylle Cocciardi, Maral Saadati, Nina Weiß, Daniela Späth et autres
ABSTRACT This study aimed to evaluate the impact of the myelodysplasia‐related gene (MRG) as well as additional gene mutations on outcomes in intensively treated patients with NPM1‐mutated (NPM1mut) AML. Targeted DNA sequencing of 263 genes was performed in 568 NPM1mut AML patients …
de, us
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Frank G. Rücker, Lars Bullinger, Sibylle Cocciardi, Sabrina Skambraks et autres
ABSTRACT: Measurable residual disease (MRD) monitoring in acute myeloid leukemia (AML) with an FLT3 internal tandem duplication (FLT3-ITDpos) has been hampered by the broad heterogeneity of ITD mutations. Using our recently developed FLT3-ITD paired-end next-generation sequencing (NGS)-based MRD assay (limit of detection …
de
(code pays fourni par la source)
Accès ouvert
2024
conference-abstract
OpenAlex
Manuela Krumbholz, Anna Dolnik, Eric Sträng, Tabita Ghete et autres
Chronic myeloid leukemia (CML) typically occurs in late adulthood. Pediatric CML is a rare form of leukemia. In all age groups, the characteristic genetic driver of the disease is the BCR::ABL1 fusion gene. However, additional genomic events contribute to leukemic transformation, which …
de
(code pays fourni par la source)
2023
conference-abstract
OpenAlex
Sibylle Cocciardi, Nina Weiß, Maral Saadati, Sabrina Skambraks et autres
Background: Mutations in the Nucleophosmin 1 gene ( NPM1 mut ) represent one of the most common genetic lesions in acute myeloid leukemia (AML).Based on its characteristic clinico-pathologic features, NPM1 mutAML has been recognized as a distinct entity among the category “AML …
de
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Frank G. Rücker, Lars Bullinger, Sibylle Cocciardi, Sabrina Skambraks et autres
Background: Internal tandem duplications of the FLT3 gene (FLT3-ITD) occurring in 10-25% of adult acute myeloid leukemia (AML) patients (pts) represent an attractive target for monitoring of measurable residual disease (MRD), particularly in pts treated with a FLT3 inhibitor. So far, MRD …
de
(code pays fourni par la source)
Accès ouvert
2021
article
OpenAlex
Susanne Lux, Tamara J. Blätte, Bernhard Gillissen, Antje Richter et autres
Circular RNAs (circRNAs) are dynamically regulated during differentiation and show cell type-specific expression, which is altered in cancer and can have a direct impact on its various hallmarks. We hypothesized that circRNA expression is deregulated in acute myeloid leukemia (AML) and that …
de
(code pays fourni par la source)
Accès ouvert
2021
article
OpenAlex
Laura K. Schmalbrock, Anna Dolnik, Sibylle Cocciardi, Eric Sträng et autres
In the international randomized phase 3 RATIFY (Randomized AML Trial In FLT3 in patients less than 60 Years old) trial, the multikinase inhibitor midostaurin significantly improved overall and event-free survival in patients 18 to 59 years of age with FLT3-mutated acute myeloid …
de, us, nl, it
(code pays fourni par la source)
Accès ouvert
2020
article
OpenAlex
Julia Herzig, Frank G. Rücker, Laura K. Schmalbrock, Tamara J. Blätte et autres
Background: FLT3-ITD occurs in ~25% of adult AML patients (pts) and is associated with poor prognosis. MRD monitoring is of high prognostic relevance, but restricted to certain AML subtypes. FLT3-ITD represents an attractive target for MRD monitoring in particular in pts treated …
de
(code pays fourni par la source)
2020
conference-abstract
OpenAlex
Anna Dolnik, Nikolaus Jahn, Eric Sträng, Sibylle Cocciardi et autres
Background: Acute myeloid leukemias (AML) with rearrangements of core-binding factor (CBF) complex genes (CBF-AML), comprising t(8;21) and inv(16) subgroups, are considered as diseases with favorable outcome. Nevertheless, CBF-AML relapse rates remain high, with ~40% of patients (pts) relapsing after standard intensive chemotherapy. …
de
(code pays fourni par la source)
Accès ouvert
2019
article
OpenAlex
Tamara J. Blätte, Laura K. Schmalbrock, Sabrina Skambraks, Susanne Lux et autres
The clinical relevance of measurable residual disease (MRD) monitoring has been well recognized in acute myeloid leukemia (AML) [ 1 ] and respective assays have been established for several recurrent leukemic markers [ 2 , 3 ]. However, although internal tandem duplications …
de
(code pays fourni par la source)
Accès ouvert
2019
article
OpenAlex
Sibylle Cocciardi, Anna Dolnik, Silke Kapp‐Schwoerer, Frank G. Rücker et autres
Abstract Mutations in thenucleophosmin 1(NPM1) gene are considered founder mutations in the pathogenesis of acute myeloid leukemia (AML). To characterize the genetic composition ofNPM1mutated (NPM1mut) AML, we assess mutation status of five recurrently mutated oncogenes in 129 pairedNPM1mutsamples obtained at diagnosis and …
de
(code pays fourni par la source)
2018
conference-abstract
OpenAlex
Tamara J. Blätte, Laura K. Schmalbrock, Sabrina Skambraks, Sibylle Cocciardi et autres
Abstract Background: In acute myeloid leukemia (AML), most patients respond to chemotherapy initially, but the risk of relapse remains high. Continued monitoring of measurable residual disease (MRD) following therapy onset enables early assessment of treatment response and clinical intervention. However, while appropriate …
de
(code pays fourni par la source)